Wedbush Predicts argenex's Q4 Earnings (NASDAQ:ARGX)

argenex SE (NASDAQ:ARGX - Free Report) - Wedbush decreased their Q4 2025 earnings per share estimates for argenex in a report released on Monday, July 21st. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $4.59 per share for the quarter, down from their previous estimate of $5.43. Wedbush currently has a "Outperform" rating and a $715.00 price target on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q1 2026 earnings at $5.10 EPS, Q2 2026 earnings at $5.66 EPS, Q3 2026 earnings at $5.15 EPS, Q4 2026 earnings at $5.64 EPS, FY2026 earnings at $21.56 EPS, FY2027 earnings at $29.32 EPS and FY2028 earnings at $44.86 EPS.

A number of other analysts also recently weighed in on ARGX. Baird R W upgraded argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Guggenheim reduced their price objective on argenex from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $720.00 price objective on shares of argenex in a report on Tuesday, July 1st. Citigroup reaffirmed a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Finally, Oppenheimer lifted their price objective on argenex from $704.00 to $708.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Nineteen research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $728.06.

argenex Stock Up 0.0%

Shares of argenex stock traded up $0.25 during trading on Thursday, reaching $591.99. The company's stock had a trading volume of 493,117 shares, compared to its average volume of 430,326. argenex has a 12-month low of $473.67 and a 12-month high of $678.21. The company has a market capitalization of $36.23 billion, a P/E ratio of 36.52, a price-to-earnings-growth ratio of 1.03 and a beta of 0.37. The business has a 50 day moving average price of $566.58 and a 200-day moving average price of $598.27.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenex had a return on equity of 16.15% and a net margin of 40.20%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. GeoWealth Management LLC lifted its holdings in argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the last quarter. Greenleaf Trust lifted its holdings in shares of argenex by 3.5% in the 1st quarter. Greenleaf Trust now owns 624 shares of the company's stock worth $369,000 after purchasing an additional 21 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after purchasing an additional 22 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of argenex by 1.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 1,829 shares of the company's stock worth $1,083,000 after purchasing an additional 24 shares during the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of argenex by 0.6% in the 1st quarter. M&T Bank Corp now owns 4,296 shares of the company's stock worth $2,542,000 after purchasing an additional 27 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.